The Medicines and Healthcare products Regulatory Agency (MHRA) announced on Tuesday that it has granted approval to an updated COVID-19 vaccine developed by Pfizer and BioNTech specifically targeting the Omicron XBB.1.5 subvariant. This vaccine, marketed under the brand name Comirnaty, is authorized for individuals aged 6 months and above. The approval from MHRA follows the clearance granted by the European regulator last week.
The U.S. and the U.K. are planning to utilize the mRNA vaccines developed by Pfizer-BioNTech and Moderna for their respective autumn immunization campaigns. These vaccines, along with a monovalent version by Novavax, target the XBB.1.5 subvariant, which was the most dominant variant earlier this year and was chosen as the primary focus for coronavirus vaccines by regulatory authorities, including the U.S. Food and Drug Administration.
(Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar and Shinjini Ganguli)
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
